KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $128.9 million.

  • Jazz Pharmaceuticals' Cost of Revenue rose 1547.25% to $128.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $485.5 million, marking a year-over-year increase of 1443.25%. This contributed to the annual value of $445.7 million for FY2024, which is 232.7% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Cost of Revenue is $128.9 million, which was up 1547.25% from $116.3 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Cost of Revenue high stood at $167.4 million for Q4 2022, and its period low was $40.2 million during Q1 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' median Cost of Revenue value was $117.7 million (recorded in 2021), while the average stood at $117.1 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Cost of Revenue skyrocketed by 32557.13% in 2021 and then crashed by 3592.23% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Cost of Revenue (Quarter) stood at $136.2 million in 2021, then grew by 22.92% to $167.4 million in 2022, then crashed by 35.92% to $107.2 million in 2023, then increased by 20.02% to $128.7 million in 2024, then increased by 0.13% to $128.9 million in 2025.
  • Its Cost of Revenue was $128.9 million in Q3 2025, compared to $116.3 million in Q2 2025 and $128.7 million in Q4 2024.